Larimar Therapeutics (LRMR) Q3 2026 earnings review
Larimar files its drug application, but cash runs out earlier
Larimar Therapeutics, a biotechnology developer with no products on the market, finished filing its rare-disease drug application while its cash reserves shrank. Chief executive Carole Ben-Maimon completed the US regulatory submission for nomlabofusp, an experimental treatment for Friedreich's ataxia, and the third-quarter net loss narrowed to $31 million as factory setup costs ended. However, cash and securities fell to $129 million, and the firm shortened its cash outlook to late in the second quarter of 2027 while pushing the target US launch to the third quarter.
| Cash and marketable securities | $128.7M down 18% from last quarter |
|---|---|
| Net loss | $31.1M $47.7M a year ago |
| Cash runway outlook | Cut late Q2 2027 vs Q3 2027 prior |
| Target US launch | Q3 2027 pushed back from mid-2027 |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because completing the regulatory filing balances a new funding gap ahead of the launch. Getting the application in on schedule with regulator backing for its protein measurement moves the drug closer to market. One caution: shortening the cash runway to late Q2 2027 while moving the launch to Q3 2027 means the money runs out before sales or a regulatory voucher payout can arrive.
The question now is whether the developer can fund the drug launch without heavily diluting shareholders before regulators rule on the application in mid-2027. Either Larimar brings in non-dilutive cash through an international licensing deal, or it issues more stock ahead of the regulatory decision and a Q1 2027 allergy update. Financing or partnership announcements over the next two quarters will tell.
🐂 Bull Case
Larimar Filed Its Drug Application with Regulator Backing
“Completing the BLA submission for nomlabofusp marks a major milestone for Larimar and the Friedreich’s ataxia (FA) community,” chief executive Carole Ben-Maimon said. A biologics license application (BLA) is a formal request asking the US Food and Drug Administration (FDA) for permission to sell a biological drug. Nomlabofusp is the biotechnology group's experimental treatment for Friedreich's ataxia, a rare genetic disease that damages the nervous system.
The company finished sending the application to regulators, "seeking accelerated approval of nomlabofusp for the treatment of FA using FXN as a novel surrogate endpoint". Frataxin (FXN) is the cellular protein that patients with the condition lack. Using a surrogate endpoint means measuring protein levels in the skin rather than waiting years to measure physical decline.
This filing matters because regulators have never approved a drug for this disease based on skin protein levels. However, the agency told Larimar in pre-filing meeting minutes that its study data package looks sufficient for review, and reaffirmed its "willingness to consider FXN as a novel surrogate endpoint". Meanwhile, the firm is enrolling patients in FORWARD-FA, a global Phase 3 trial designed to confirm the clinical benefit.
What to watch: the agency's decision to accept the application for review in early 2027. Acceptance would confirm that the filing is complete and set a mid-2027 target date for an approval decision.
Factory Spending Dropped After Commercial Scale-Up Finished
As a clinical-stage developer with no products on the market, Larimar generates no revenue and loses money every quarter. Research and development is its largest cost, paying for clinical trials and contract drug factories.
Research and development spending fell 42.3% from a year ago to $25.9 million in the third quarter, and declined 7.4% from the second quarter. The drugmaker said the drop came from a $19.3 million "decrease in drug manufacturing activities at our third-party manufacturers". Last year, the firm spent heavily to qualify its commercial-scale manufacturing process ahead of the regulatory filing.
Because those factory qualification runs are finished, quarterly cash burn slowed. By our math, the balance of cash and marketable securities fell by $27.6 million in the third quarter, down from a $44.1 million drop in the second quarter. Lower factory bills allow the developer to shift money toward its confirmatory trial and sales preparation without raising total spending.
What to watch: fourth-quarter research and development expenses. A reading near $26 million would show that the global Phase 3 trial enrollment is not driving total research costs back to last year's levels.
🐻 Bear Case
Cash Runs Out Before the Planned Drug Launch
Larimar ended September with $128.7 million in cash, cash equivalents and marketable securities, down 17.7% from $156.3 million in June. Management uses this reserve to fund ongoing clinical trials, regulatory reviews, and commercial preparations.
In this release, the company changed two timelines in opposite directions. It shortened its "projected cash runway into late Q2 2027", compared with a projection into the third quarter of 2027 just three months ago. At the same time, it pushed its target US commercial launch back to the third quarter of 2027, having targeted mid-2027 in the prior quarter and the first half of 2027 earlier this year.
- Cash and marketable securities: $128.7 million, down $27.6 million from last quarter by our math
- Cash runway outlook: late Q2 2027, shortened from Q3 2027 in the prior release
- Target US launch: Q3 2027, pushed back from mid-2027 in the prior release
- Target voucher sale: mid-2027, contingent on receiving drug approval first
This timing gap cuts against the picture of a smooth transition to commercial sales, because the existing money runs out before the drug reaches the market. Even though the third-quarter burn of $27.6 million would last 4.7 quarters by our math, management's late Q2 2027 cutoff shows that spending will rise over the next three quarters. The firm plans to obtain and sell a pediatric priority review voucher in mid-2027, but it only gets that voucher upon drug approval. Therefore, Larimar will likely need to raise money or sign a partnership before regulators decide on the drug.
What to watch: any financing announcement or licensing deal for markets outside the US before mid-2027. Raising cash before the regulatory decision would remove the funding gap but increase the share count again.
Allergic Reactions and Patient Dropouts Remain Undisclosed
To support its regulatory filing, Larimar runs an open-label study where all patients receive daily injections of nomlabofusp. In previous quarters, the main safety risk in this trial has been anaphylaxis, a severe and potentially life-threatening allergic reaction.
In the first quarter of 2026, the company reported that 7 out of 39 study participants had experienced anaphylaxis, prompting a change to a lower starting dose. By the second quarter, total participants rose to 43, and discontinuations due to anaphylaxis reached 10, with only 22 active patients remaining in the trial. In the third quarter release, the drugmaker said enrollment continues and that it presented open-label findings at a medical congress in November, but it gave no updated patient counts or allergy numbers.
The absence of safety numbers matters because high dropout rates could limit how doctors use the drug or lead regulators to require strict warning labels. Instead of updating the figures in the quarterly report, the company listed an open-label study safety update as a milestone for the first quarter of 2027.
What to watch: the open-label safety update in the first quarter of 2027. A rise in anaphylaxis cases above 10 among new patients would show that the modified starting dose has not solved the allergic reactions.
👓 Other Themes
Sales Preparation Lifted Overhead Costs by 43%
General and administrative expenses — the overhead costs of running the company and preparing to sell the drug — rose 43.1% from a year ago to $6.5 million. Larimar attributed the increase to an "acceleration of commercial activities as we prepare for the third quarter 2027 launch of nomlabofusp, if approved". That added $0.6 million in commercial consulting, $0.5 million in legal fees, and $0.3 million in commercial staff pay, lifting overhead to 20.1% of total operating expenses by our math.
💲 Other KPIs
Net loss narrowed by 34.7% from $47.7 million a year ago, and shrank slightly from $32.8 million in the second quarter. Lower third-party drug manufacturing bills drove the reduction. Loss per common share fell 52.5% from $0.61 a year ago, helped by both the smaller loss and a larger share count.
The average common share count rose 33.1% from 78.3 million a year ago, though it held nearly steady against 103.9 million in the second quarter. The year-over-year increase reflects stock offerings in July 2025 and February 2026 that raised $172.6 million in combined net proceeds to fund clinical trials.
Accrued expenses — bills the biotech group has recorded in its accounts but not yet paid in cash — dropped 50.1% from $58.5 million at the end of 2025. Paying down those accumulated manufacturing bills during the first half of 2026 used cash beyond the reported operating losses, though total liabilities stabilized at $39.0 million this quarter.
🔮 Guidance
Cut. The company now expects its $128.7 million in cash and securities to last into late in the second quarter of 2027, shortened by about one quarter from its prior projection. By our math, the third-quarter cash burn of $27.6 million would cover 4.7 quarters, so the shorter timeline implies quarterly cash spending will rise over the next nine months.
Cut. The developer now targets a third-quarter 2027 launch in the US if regulators approve the drug. It is the second time the target has moved back this year: in the first quarter the plan called for the first half of 2027, and in the second quarter it called for mid-2027.
New. Following the completion of its rolling application in November 2026, management expects the FDA to formally accept the file for review in early 2027.
New. The drugmaker plans to release updated safety data from its ongoing open-label trial in the first quarter of 2027.
New. Management targets a regulatory approval decision in mid-2027. If approved, the firm expects to receive a Rare Pediatric Disease Priority Review Voucher — a transferable ticket for faster regulatory review that drugmakers often sell to larger pharmaceutical companies for cash — and monetize it in mid-2027.
❓ Key Questions
How will Larimar bridge the cash gap before approval?
Cash runs out in late Q2 2027, before the targeted mid-2027 approval, voucher sale, and Q3 2027 launch. Will management seek an ex-US partnership or issue more stock to fund the third quarter?
Have any new patients suffered severe allergic reactions?
By June 2026, 10 of 43 open-label study patients had stopped treatment due to anaphylaxis. Why did the third-quarter release omit updated patient and allergy counts ahead of the Q1 2027 safety update?
How many patients are enrolled in the Phase 3 trial?
The company confirmed that patients are enrolling in FORWARD-FA, which targets 100 to 150 participants globally. How many patients have been dosed so far, and when is enrollment expected to finish?
Why did the cash runway shrink as quarterly burn fell?
Quarterly cash burn dropped to $27.6 million by our math, yet the runway outlook moved back from Q3 2027 to late Q2 2027. Which specific costs will rise over the next two quarters?
